
Amikacin Sulphate Injection treat some serious bacterial infections in patients when caused by bacteria that are sensitive to Amikacin Sulphate. It causes the breakdown of bacterial proteins, which interrupts bacterial protein synthesis. This medicine is intended to be used only in a hospital or in another setting where treatment with an aminoglycoside is needed.
Composition of Amikacin Sulphate Injection
Active Pharmaceutical Ingredient:
Amikacin Sulphate: equivalent to the labelled amount of amikacin.
Available Strength: 100 mg/2 mL
Amikacin Sulphate Injection is provided as an injectable preparation. Please check concentration and presentation against the product packaging and your prescription before use.
Amikacin is an aminoglycoside antibiotic. It works by binding to the 30S subunit of the bacterial ribosome, disrupting the production of bacterial proteins and leading to errors in the synthesis of the bacteria’s proteins. This kills the bacteria that are sensitive to it.
The activity of Amikacin is dependent on the causative organism and its sensitivity to antibiotics. Infection by a bacterium that may be treated with an aminoglycoside, including some infections caused by antibiotic-resistant bacteria, can sometimes be treated with Amikacin.
Amikacin Sulphate Injection may be used for the treatment of some serious bacterial infections in patients with susceptible bacteria. Uses as permitted by the authorised prescribing information and as appropriate to the individual patient may include:
Treatment choice should depend on the patient’s situation, the results of microbiological testing, and clinical guidelines that are relevant. Amikacin may not be suitable for treating viral infections.
Amikacin Sulphate Injection should be given by a healthcare professional in the approved way (such as through infusion into a vein or by injection into a muscle) via the route and strength for the indication (reason for treatment), per the product information. Don’t try to give this medicine yourself.
Amikacin sulphate injection is dosed depending on the total body weight of the patient, severity of the infection, the route of administration, and the clinical response to therapy. Dose modifications may be required in cases of renal impairment. Amikacin blood concentrations can be monitored during therapy if required. This may help minimise toxicity during lengthy courses of therapy or in patients at higher risk.
Neuromuscular blockade in some patients. Kidney toxicity and damage to the hearing or balance organ are severe and often irreversible. Symptoms such as changes in hearing, dizziness, or reduced urine should be checked out by a doctor as soon as possible.
Kidney function: Renal function should be checked before and at appropriate times during treatment.
Hearing and balance: Monitor patients carefully who have pre-existing hearing or balance disorders.
Other medicines: Please tell your doctor if you are taking any other medicines that could interfere with kidney function or hearing.
Pregnancy: The risk/benefit of treatment should be carefully assessed for each woman.
It is an aminoglycoside antibiotic used to treat specific infections caused by bacteria that are sensitive to this medicine.
The prescribed strength is 100 mg/2 mL. Confirm the specific formulations from the label of an approved product.
It acts by inhibiting bacterial protein synthesis by binding to the 30S subunit of the bacterial ribosome and hence helps to kill sensitive bacteria.
It is given in the form of an injection into a muscle or vein by a medical professional.
Kidney function, hearing, and balance should be taken into account, as Amikacin may cause kidney toxicity and hearing and balance damage.